Crescent Bioformulations Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 1.20 Cr
as on 31-07-2024
- Paid Up Capital ₹ 0.76 Cr
as on 31-07-2024
- Company Age 12 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.02 Cr
as on 31-07-2024
- Satisfied Charges ₹ 1.75 Cr
as on 31-07-2024
- Revenue -2.85%
(FY 2023)
- Profit -88.09%
(FY 2023)
- Ebitda 12.66%
(FY 2023)
- Net Worth -0.40%
(FY 2023)
- Total Assets 3.45%
(FY 2023)
About Crescent Bioformulations
The Company is engaged in the Professional Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.20 Cr and a paid-up capital of Rs 0.76 Cr.
The company currently has active open charges totaling ₹3.02 Cr. The company has closed loans amounting to ₹1.75 Cr, as per Ministry of Corporate Affairs (MCA) records.
Sagar Mishra, Anurag Mishra, and Anurag Bajpai serve as directors at the Company.
- CIN/LLPIN
U24233UP2011PTC046931
- Company No.
046931
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Oct 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Kanpur, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Crescent Bioformulations Private Limited offer?
Crescent Bioformulations Private Limited offers a wide range of products and services, including Animal Medicines & Health Care, Animal Nutraceuticals, Bird Food, Poultry & Animal Food, Animal Feed Supplement, Veterinary Medicines, Hand Sanitizers & Personal Hygiene, Beauty Soap, Feed Additives.
Who are the key members and board of directors at Crescent Bioformulations?
Board Members(3)
Financial Performance and Corporate Structure Insights of Crescent Bioformulations.
Crescent Bioformulations Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 2.85% decrease. The company also saw a substantial fall in profitability, with a 88.09% decrease in profit. The company's net worth dipped by a decrease of 0.4%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Crescent Bioformulations?
In 2022, Crescent Bioformulations had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Chemaxon Biosis Private Limited
Active
5 years 1 month Sagar Mishra and Anurag Mishra are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 26 Feb 2024 | ₹1.38 M | Open |
Sidbi Creation Date: 28 Dec 2023 | ₹1.00 Cr | Open |
Sidbi Creation Date: 01 Dec 2021 | ₹3.85 M | Open |
How Many Employees Work at Crescent Bioformulations?
Unlock and access historical data on people associated with Crescent Bioformulations, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
As of Jul 10, 2020, Crescent Bioformulations has raised a total of ₹ 1.32 Cr, with the most recent deal valued at ₹ 1.82 M. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
